Drug Delivery Systems on Leprosy Therapy: Moving Towards Eradication?
Luíse Lopes Chaves, Yuri Basílio Gomes Patriota, José Lamartine Soares‐Sobrinho, Alexandre C.C. Vieira, Sofia A. Costa Lima, Salette Reis
Pharmaceutics · 2020-12
Abstract
, the causative agent of leprosy, presents tropism for cells of the reticuloendothelial and peripheral nervous system. Current multidrug therapy consists of clofazimine, dapsone and rifampicin. Despite significant improvements in leprosy treatment, in most programs, successful completion of the therapy is still sub-optimal. Drug resistance has emerged in some countries. This review discusses the status of leprosy disease worldwide, providing information regarding infectious agents, clinical manifestations, diagnosis, actual treatment and future perspectives and strategies on targets for an efficient targeted delivery therapy.
MeSH terms
- Leprosy
- Clofazimine
- Mycobacterium leprae
- Medicine
- Dapsone
- Rifampicin
- Intensive care medicine
- Drug resistance
- Disease
- Tuberculosis
- Immunology
- Pharmacotherapy
- Drug